Deborah Waterhouse, ViiV Healthcare CEO

GSK's Vi­iV to lean on long-act­ing HIV port­fo­lio ahead of do­lute­gravir patent ex­pi­ra­tion

GSK’s Vi­iV Health­care is eye­ing 2026 and 2027 for po­ten­tial longer-act­ing ver­sions of its re­spec­tive HIV in­jecta­bles for pre­ven­tion and treat­ment, ex­ec­u­tives said on a me­dia call Wednes­day.

The ef­fort is part of GSK’s plan to bounce back from a key patent ex­pi­ra­tion in April 2028 for do­lute­gravir, its block­buster oral in­te­grase in­hibitor. It launched in 2013 as Tivicay and is now a key com­po­nent of GSK’s two-drug HIV treat­ments: Dova­to and Ju­lu­ca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA